Investigational Drug Retatrutide Shows 'Unprecedented' Weight Loss in Phase 2 Trials

Early clinical trial data for Retatrutide, an investigational triple-hormone injection, indicates significant weight reduction, with some participants losing up to 30% of their body weight over 80 weeks. The drug targets GLP-1, GIP, and glucagon receptors. It is currently in global Phase 3 trials and not yet FDA-approved.